FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Novo's CagriSema Injection Demonstrates 25% Weight Loss in Women

      Novo Nordisk has announced promising results from late-stage trials of its experimental obesity drug, CagriSema. The new injection reportedly achieves a 25% weight loss in women, surpassing the effectiveness of the company's existing GLP-1 obesity treatment, Wegovy.

      The findings suggest that CagriSema could represent a significant advancement in obesity treatment, potentially offering patients a more effective option for weight management. Novo Nordisk's ongoing research aims to address the growing global obesity epidemic, which affects millions of individuals worldwide.

      As the pharmaceutical industry continues to explore innovative solutions for obesity, Novo's latest results may pave the way for regulatory approvals and broader market availability in the near future.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud